Lilly’s Mounjaro more effective than Ozempic for weight loss in study, CNBC says

Eli Lilly’s (LLY) diabetes drug Mounjaro is more effective for weight loss than Novo Nordisk’s (NVO) Ozempic in overweight or obese adults, according to a large analysis of real-world data, CNBC’s Annika Kim Constantino reports. Patients taking Mounjaro were significantly more likely to lose 5%, 10% and 15% of their body weight overall and saw larger reductions in body weight after three months, six months and a year compared with those on Ozempic in the study by Truveta Research. The study is not yet peer-reviewed, CNBC notes.